Skip to main content

CLINICAL TRIAL article

Front. Surg.
Sec. Orthopedic Surgery
Volume 11 - 2024 | doi: 10.3389/fsurg.2024.1470205

Clinical value of esketamine combined with ropivacaine in rebound pain after brachial plexus block in patients with upper limb fractures

Provisionally accepted
Shiyao Zhu Shiyao Zhu 1Dan Wang Dan Wang 1Haiyan Gao Haiyan Gao 1Lei Heng Lei Heng 1Weikang Shui Weikang Shui 2Shanshan Zhu Shanshan Zhu 1*
  • 1 Xuzhou Cancer Hospital, Xuzhou, Jiangsu Province, China
  • 2 Xuzhou Medical University, Xuzhou, Jiangsu Province, China

The final, formatted version of the article will be published soon.

    To analyze the clinical value of the combination of esketamine and ropivacaine in alleviating rebound pain in patients with upper limb fractures following brachial plexus block. A total of 149 patients with unilateral upper limb fractures who underwent open reduction and internal fixation surgery under brachial plexus block anesthesia from November 2021 to August 2022 were selected as the subjects for the study and randomly divided into the esketamine group (RNK group) and the ropivacaine group (R group). The incidence of rebound pain at 48 hours postoperatively, intraoperative mean arterial pressure (MAP) and heart rate (HR), the onset time and duration of blockade, the Numeric Rating Scale (NRS) scores for pain at rest and with activity during the perioperative period, the dosage, numbers of compressions, and effective compressions of postoperative patient-controlled analgesia with sufentanil, and occurrence of adverse reactions were assessed and compared between the two groups. The incidence of rebound pain in the RNK group was lower than that in the R group (P<0.05). The RNK group exhibited higher MAP and HR at 5 min and 10 min after anesthesia compared to the R group (P<0.05). The RNK group had faster onset time and longer duration of sensory and motor blockade compared to the R group (P<0.05). The NRS scores at rest and with activity at 12 h and 24 h postoperatively in the RNK group were lower than those in the R group (P<0.05). The total numbers of compressions, effective numbers of compressions, and dosage of sufentanil postoperatively were lower in the RNK group compared to the R group (P<0.05). The incidence of adverse reactions in the RNK group did not differ significantly from that in the R group (P>0.05). The combination of esketamine and ropivacaine demonstrates a favorable preventive effect on rebound pain in patients with upper limb fractures following brachial plexus block, which is conducive to reducing the incidence of rebound pain, shortening the onset time of blockade, and prolonging the duration of blockade.

    Keywords: brachial plexus block, Esketamine, rebound pain, Ropivacaine, Upper limb fractures

    Received: 25 Jul 2024; Accepted: 24 Oct 2024.

    Copyright: © 2024 Zhu, Wang, Gao, Heng, Shui and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Shanshan Zhu, Xuzhou Cancer Hospital, Xuzhou, Jiangsu Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.